Why the study?
Several recent RCTs have investigated DOACs for malignancy-associated VTE, warranting a meta-analysis combining all RCT data to evaluate the risks of recurrent VTE and bleeding compared with LMWH.
Do direct oral anticoagulants (DOAC) reduce recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with malignancy-associated VTE?
Do direct oral anticoagulants (DOAC) reduce recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with malignancy-associated VTE?
DOACs are effective for treating malignancy-associated VTE, reducing recurrent VTE compared to LMWH, though they may increase the risk of clinically relevant non-major bleeding.
Answers are grounded in this paper and cite their sources.
Supports DOACs over LMWH for cancer-associated VTE; reinforces RCT data while highlighting bleeding trade-offs.
Background Several recent randomised controlled trials (RCT) have investigated the use of direct oral anticoagulants (DOAC) in the treatment of malignancy‐associated venous thromboembolism (VTE). Aims This meta‐analysis combines all RCT data to determine the risks of recurrent VTE and bleeding with DOAC in patients with malignancy‐associated VTE compared with low‐molecular‐weight heparin (LMWH). Methods The study followed PRISMA guidelines. MEDLINE, EMBASE and CENTRAL were systematically searched from inception to 1 April 2020. References of reviews and relevant conference proceedings were searched by hand. Two authors independently evaluated study eligibility, extracted data and assessed risk of bias. Direct and indirect meta‐analyses were performed. Results In four RCT with low risk of bias (2907 patients), high certainty evidence suggested that DOAC had a 37% reduction in risk of recurrent VTE compared with LMWH (direct pooled risk ratio (RR) 0.63; 95% confidence interval (CI) 0.44–0.91; I 2 = 28%). No significant difference was observed in the risk of major bleeding with DOAC compared with LMWH (RR 1.31; 95% CI 0.83–2.07; I 2 = 22%; moderate certainty evidence), including in patients in gastrointestinal and genitourinary malignancy. An increased risk of combined major or clinically relevant non‐major bleeding was seen with DOAC (RR 1.52; 95% CI 1.09–2.12; I 2 = 51%; low certainty evidence). Apixaban had the highest probability of being ranked the most effective and least bleeding risk among the DOAC. Conclusion DOAC are effective in treating malignancy associated VTE; however, caution is required in patients with high risk of bleeding. Apixaban had lower risk of bleeding compared to other DOAC in this population.
No takes yet. Share an insight, caveat, or question.
Samaranayake et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: